Decisions involved in non-adherence to the guidelines
| Non-adherence | Total | ||
|---|---|---|---|
| NA− | NA+ | ||
| NA−, patients with a cumulative methotrexate dose at the end of the trial period that was lower than the guidelines proposed; NA+, patients with a cumulative methotrexate dose at the end of the trial period that was higher than the guidelines proposed. | |||
| Patients (n) | 102 | 101 | 203 |
| Decisions (n) | 201 | 189 | 390 |
| Specification of decisions | |||
| Restart with less than last tolerated dose | 6 | 6 | |
| Restart with more than last tolerated dose | 3 | 22 | 25 |
| No increase, though not a good response | 132 | 26 | 158 |
| No increase, for other reasons | 15 | 17 | 32 |
| Increased, though good response | 1 | 43 | 44 |
| Increased by 5.0 mg/week | 15 | 15 | |
| Increased by 7.5 mg/week | 3 | 3 | |
| Premature increase | 30 | 45 | 75 |
| Dose above 25 mg/week | 6 | 6 | |
| Decrease below last tolerated dose | 8 | 1 | 9 |
| Decrease too small | 1 | 1 | |
| Decrease by patient initiative | 1 | 1 | |
| No temporarily halt, though moderate adverse event | 6 | 6 | |
| No decrease, though mild adverse event | 3 | 3 | 6 |
| Unjustified temporarily stop | 2 | 2 | |